CMK SELECT
43 Route 46 East, Suite 705 Pine Brook, NJ 07058 USA
Rachel Phone: (973) 244-6060

FORGOT YOUR DETAILS?

+ Filters

Select one or more of the filter options below

CLOSE

Thought Leadership

Five Common Barriers to Optimal Launch Trajectory (Part 1)

AUTHOR: B.Turakhia

New Drug Launch, Day 1… The most anticipated and pivotal day for a pharmaceutical company. It takes an average of 14 years and $2.6 billion…

CONTINUE READING

Case for an IT-enabling Business Strategy for companies in the Life Sciences Industry

AUTHOR: D. Douglas

The major trends in the life sciences industry are profoundly affecting the way we all work – from conducting research to distributing products, and everything…

CONTINUE READING

The Rising Value of Medical Affairs – Engagement with External Stakeholders (KOLs, TLs, EEs)

AUTHOR: N. Borinshteyn

The ever-evolving relationship between the pharmaceutical industry and its key opinion leaders (KOLs) has been a hot topic for a while, and there are several…

CONTINUE READING

The Continuously Increasing Value of Medical Affairs in Product Launches – Part I

AUTHOR: N. Borinshteyn

Bringing each new pharmaceutical product to market is a complex and somewhat unique process led and executed by a cross-functional team who undertakes a number…

CONTINUE READING

The Rising Value of Medical Affairs

AUTHOR: N. Borinshteyn

It’s not news that market pressures are driving the healthcare industry’s increasing medical orientation. Recognized trends that are leading this shift include: Growing prevalence of…

CONTINUE READING

Understanding the Healthcare Transaction Model – Part 1

AUTHOR: CMK SELECT

All healthcare transactions begin with the consumer. By transaction, I mean the literal interpretation of the word – taking an action across a set of…

CONTINUE READING

Ensuring Launch Success with KPIs

AUTHOR: D. Yerranguntla

KPIs, or key performance indicators, are critical to the success of a pharmaceutical product launch. By their very definition, KPIs are measurable values that demonstrate…

CONTINUE READING

Five Common Barriers to Optimal Launch Trajectory (Part 2 of 2)

AUTHOR: B.Turakhia

Fifty percent of new drug launches do not achieve peak sales, with half of them missing their targeted goals by 50% or more.1 How can…

CONTINUE READING

Five Best Practices for Maintaining Sunshine Act Compliance

AUTHOR: CMK SELECT

How drug companies can avoid penalties, revenue loss, resource drain, reputation issues, and relationship challenges With the passing of the Physician Payments Sunshine Act, the…

CONTINUE READING

Alignment Creates the Foundation for Launch Excellence

AUTHOR: B.Turakhia

When you’re launching a product into a competitive market, you plan on nothing less than great success. You know that making a major impact at…

CONTINUE READING

LIKE OUR PAGE

FOLLOW US

GET LINKED IN

TOP